Merck expects China biz to outpace market; Sanofi board key to Genzyme deal;

 @FiercePharma: Breast cancer patients press FDA to keep Avastin. Article | Follow @FiercePharma

> Merck & Co expects to grow as fast or faster than China's broader pharmaceutical market, now expanding by more than 20 percent each year, as Beijing rolls out a new healthcare system and an emerging middle class spends more money on medicine. Story

> An oil major, a luxury cosmetics company and independent Sanofi-Aventis directors including a former astronaut will have a key say in what may be the next multibillion-dollar merger to shake the global pharmaceutical industry. Report

> Shire expects to feel little if any impact from an FDA investigation into the safety of hyperactivity medicines, scheduled for release early next year. Item

> Novo Nordisk has launched an iPhone app for U.S. healthcare professionals that enables them to look up dosing guidelines for their patients with diabetes. Article

> Lawyers suing drug maker Bayer claim they have good reasons to investigate a product they haven't sued over, but their reasons remain secret. Article

Biotech News

@FierceBiotech: Bluebird in spotlight after gene therapy cures blood disorder. Article  | Follow @FierceBiotech

> Cell Therapeutics gets OK to sell more shares. News

> Crucell eagerly accepts $2.3B buyout offer from J&J. Story

> Transition, Lilly kill diabetes program after trial failure. Article

> Arena fails to convince FDA panel on obesity drug. News

> Burrill to Minnesota: No ink on that $1B biopark contract. Report

> Explosive Chinese market inspires new Merck pact on personalized meds. Story

And Finally... Pfizer is looking to make more bucks from Fido, Fifi and farm animals. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.